<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32284607</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72.</ArticleTitle><Pagination><StartPage>615</StartPage><EndPage>624</EndPage><MedlinePgn>615-624</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-020-0619-5</ELocationID><Abstract><AbstractText>Hexanucleotide expansions in C9orf72, which encodes a predicted guanine exchange factor, are the most frequent genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Although repeat expansion has been established to generate toxic products, mRNAs encoding the C9ORF72 protein are also reduced in affected individuals. In this study, we tested how C9ORF72 protein levels affected repeat-mediated toxicity. In somatic transgenic mice expressing 66 GGGGCC repeats, inactivation of one or both endogenous C9orf72 alleles provoked or accelerated, respectively, early death. In mice expressing a C9orf72 transgene with 450 repeats that did not encode the C9ORF72 protein, inactivation of one or both endogenous C9orf72 alleles exacerbated cognitive deficits, hippocampal neuron loss, glial activation and accumulation of dipeptide-repeat proteins from translation of repeat-containing RNAs. Reduced C9ORF72 was shown to suppress repeat-mediated elevation in autophagy. These efforts support a disease mechanism in ALS/FTD resulting from reduced C9ORF72, which can lead to autophagy deficits, synergizing with repeat-dependent gain of toxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jiang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania F</ForeName><Initials>TF</Initials><Identifier Source="ORCID">0000-0002-7335-2627</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAlonis-Downes</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lulin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz Garcia</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh Dastidar</LastName><ForeName>Somasish</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Neuroscience; Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yongjie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Spada</LastName><ForeName>Albert R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology, Neurobiology, and Cell Biology, Duke Center for Neurodegeneration and Neurotherapeutics, Duke University School of Medicine, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravits</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Da Cruz</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagier-Tourenne</LastName><ForeName>Clotilde</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3058-8322</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The Sean M. Healey and AMG Center for ALS at Mass General, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. clagier-tourenne@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard University and MIT, Cambridge, MA, USA. clagier-tourenne@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Don W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0002-1934-3682</Identifier><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, CA, USA. dcleveland@ucsd.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California at San Diego, La Jolla, CA, USA. dcleveland@ucsd.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA, USA. dcleveland@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS087227</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD012351</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA013696</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS099114</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021764</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS027036</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2020 May;23(5):596-597</RefSource><PMID Version="1">32313266</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>COMPETING FINANCIAL INTERESTS. D.W.C. is a consultant for Ionis Pharmaceuticals. The other authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32284607</ArticleId><ArticleId IdType="mid">NIHMS1608453</ArticleId><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-0619-5</ArticleId><ArticleId IdType="pii">10.1038/s41593-020-0619-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TP, Daniels RD, Gatta AT, Wong LH &amp; Hayes MJ The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 29, 499&#x2013;503 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570213</ArticleId><ArticleId IdType="pubmed">23329412</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proceedings of the National Academy of Sciences of the United States of America 108, 260&#x2013;265 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proceedings of the National Academy of Sciences of the United States of America 110, E4968&#x2013;4977 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta neuropathologica 126, 881&#x2013;893 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R &amp; Isaacs AM C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 14, 544&#x2013;558 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta neuropathologica 130, 845&#x2013;861 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N &amp; Lagier-Tourenne C Nuclear pores: the gate to neurodegeneration. Nat Neurosci 21, 156&#x2013;158 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29371653</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, et al. Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathol 135, 459&#x2013;474 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta neuropathologica 126, 859&#x2013;879 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proceedings of the National Academy of Sciences of the United States of America 110, E4530&#x2013;4539 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojciechowska M &amp; Krzyzosiak WJ Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum Mol Genet 20, 3811&#x2013;3821 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168290</ArticleId><ArticleId IdType="pubmed">21729883</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ &amp; Rothstein JD The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat Rev Neurosci 17, 383&#x2013;395 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7376590</ArticleId><ArticleId IdType="pubmed">27150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Burguete AS, et al. GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. Elife 4, e08881 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758954</ArticleId><ArticleId IdType="pubmed">26650351</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron 90, 535&#x2013;550 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, et al. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron 90, 521&#x2013;534 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 348, 1151&#x2013;1154 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil VV, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta neuropathologica 126, 895&#x2013;905 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830740</ArticleId><ArticleId IdType="pubmed">24166615</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415&#x2013;428 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick P, et al. Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathol Commun 6, 72 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091050</ArticleId><ArticleId IdType="pubmed">30075745</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite AJ, et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging 35, 1779 e1775&#x2013;1779 e1713 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet 92, 981&#x2013;989 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675239</ArticleId><ArticleId IdType="pubmed">23731538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta neuropathologica 129, 715&#x2013;727 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25716178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol 74, 180&#x2013;187 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M, Rouleau GA, Dion PA &amp; Parker JA Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS One 8, e83450 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861484</ArticleId><ArticleId IdType="pubmed">24349511</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science 351, 1324&#x2013;1329 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Scientific reports 6, 23204 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugolino J, et al. Loss of C9orf72 Enhances Autophagic Activity via Deregulated mTOR and TFEB Signaling. PLoS genetics 12, e1006443 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119725</ArticleId><ArticleId IdType="pubmed">27875531</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med 8, 347ra393 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, et al. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol Commun 4, 51 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4870812</ArticleId><ArticleId IdType="pubmed">27193190</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M, et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann Neurol 78, 426&#x2013;438 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med 24, 313&#x2013;325 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C, et al. Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. The EMBO journal 35, 1276&#x2013;1297 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910533</ArticleId><ArticleId IdType="pubmed">27103069</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, et al. A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. Sci Adv 2, e1601167 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010369</ArticleId><ArticleId IdType="pubmed">27617292</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CP, et al. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. The EMBO journal 35, 1656&#x2013;1676 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969571</ArticleId><ArticleId IdType="pubmed">27334615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis. Genes Dev 32, 929&#x2013;943 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075033</ArticleId><ArticleId IdType="pubmed">29950492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho WY, et al. The ALS-FTD-linked gene product, C9orf72, regulates neuronal morphogenesis via autophagy. Autophagy, 1&#x2013;16 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526867</ArticleId><ArticleId IdType="pubmed">30669939</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta neuropathologica 128, 525&#x2013;541 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161616</ArticleId><ArticleId IdType="pubmed">24806409</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Iyer LM, He F &amp; Aravind L Discovery of Novel DENN Proteins: Implications for the Evolution of Eukaryotic Intracellular Membrane Structures and Human Disease. Frontiers in genetics 3, 283 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521125</ArticleId><ArticleId IdType="pubmed">23248642</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz J, Niibori Y, P WF &amp; J PL Rotarod training in mice is associated with changes in brain structure observable with multimodal MRI. Neuroimage 107, 182&#x2013;189 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25497397</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Yang DS &amp; Lee JH Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 4, 590&#x2013;599 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18497567</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1&#x2013;222 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835977</ArticleId><ArticleId IdType="pubmed">26799652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A The ubiquitin-proteasome proteolytic pathway. Cell 79, 13&#x2013;21 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7923371</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitiprolu M, et al. A complex of C9ORF72 and p62 uses arginine methylation to eliminate stress granules by autophagy. Nat Commun 9, 2794 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052026</ArticleId><ArticleId IdType="pubmed">30022074</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J &amp; Ravits J Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. Neurotherapeutics 16, 1115&#x2013;1132 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985338</ArticleId><ArticleId IdType="pubmed">31667754</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassif M, Woehlbier U &amp; Manque PA The Enigmatic Role of C9ORF72 in Autophagy. Front Neurosci 11, 442 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541066</ArticleId><ArticleId IdType="pubmed">28824365</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr. &amp; Cleveland DW Decoding ALS: from genes to mechanism. Nature 539, 197&#x2013;206 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy Sarkar S &amp; Banerjee S Gut microbiota in neurodegenerative disorders. J Neuroimmunol 328, 98&#x2013;104 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30658292</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>METHODS-ONLY REFERENCES</Title><Reference><Citation>Kramer NJ, et al. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science 353, 708&#x2013;712 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5823025</ArticleId><ArticleId IdType="pubmed">27516603</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 83, 1043&#x2013;1050 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, et al. Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta neuropathologica 130, 559&#x2013;573 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575385</ArticleId><ArticleId IdType="pubmed">26350237</ArticleId></ArticleIdList></Reference><Reference><Citation>Parone PA, et al. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. J Neurosci 33, 4657&#x2013;4671 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711648</ArticleId><ArticleId IdType="pubmed">23486940</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao C, et al. Mitotic recombination produces the majority of recessive fibroblast variants in heterozygous mice. Proceedings of the National Academy of Sciences of the United States of America 96, 9230&#x2013;9235 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17762</ArticleId><ArticleId IdType="pubmed">10430925</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LL, et al. Membralin deficiency dysregulates astrocytic glutamate homeostasis leading to ALS-like impairment. J Clin Invest 129, 3103&#x2013;3120 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6668683</ArticleId><ArticleId IdType="pubmed">31112137</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>